SAN DIEGO — Stereotactic ablative body radiotherapy (SABR) was an effective, noninvasive strategy for treating primary renal cell carcinoma (RCC) in patients who were not suitable… Read More
Telix Pharmaceuticals has announced the initiation of a pivotal Phase III registration study for TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) in China. The study aims… Read More
MELBOURNE, Australia, Aug. 23, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June… Read More
Image-Guided Surgery Devices Market
The global Image-Guided Surgery Devices Market was valued at USD 5,540.87 million in 2021 and growing at a CAGR of 5.81% during the forecas… Read More
[Research Report] The radioactive tracer market is expected to grow from US$ 14,675.73 million in 2022 to US$ 54,296.57 million by 2030; it is expected to grow at a CAGR of 17.8% from 2… Read More
Monash has been awarded a total of almost $15 million to establish two Australian Research Council (ARC) Industrial Transformation Research Hubs and one ARC Industrial Transformation Trainin… Read More
The University of Queensland’s Centre for Advanced Imaging (CAI) has launched an Australian-first facility that will use radiometals for cancer therapy.
CAI deputy director (researc… Read More
MELBOURNE, Australia, June 18, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase… Read More
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its artificial intelligence (AI) capability with the signing of an agreement to acquire&nbs… Read More
There was bad news and good news in a phase III trial evaluating intensive chemotherapy with or without gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia (AML) patients with newly… Read More
Victorian based Neuren Pharmaceuticals’ North American partner, Acadia Pharmaceuticals, has received news this week that its treatment for Rett syndrome was approved by the US Food and… Read More
“Radiopharmaceutical Theranostics Market” study by “The Insight Partners” provides details about the market dynamics affecting the market, Market scope, Market segmen… Read More
Melbourne-based Telix Pharmaceuticals has been one of the largest recipients of the R&D Tax incentive, and has now achieved a rare feat in Biotechnology; commercialising a product… Read More
New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare’s immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy tr… Read More
AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards
Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO Company of the Year: Telix … Read More
The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period. Certain factors that are driving the market growth include increased awareness about the p… Read More
Telix Pharmaceuticals Limited today announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON (Zirconium in Renal Cancer Oncology, NCT03… Read More
Melbourne based Paradigm Biopharmaceuticals has reported receipt of a $8.2 million research and development tax incentive refund for the YE 30 June 2021 relating to ongoing R&D activitie… Read More
Introduction
The global nuclear imaging market is growing at a substantial pace where the scope of nuclear imaging is luminous in the radiology procedures. Nuclear imaging means scanning and… Read More
The global radiopharmaceuticals market is growing pervasively, mainly due to the rising importance of radiotracers in treatments of cancer and cardiovascular diseases. The emergence of advan… Read More